Pancreatic Cancer Brief — Daraxonrasib trial doubles survival — access expanding now
Digest Newsletter
·
Jun 13, 2026
Pancreatic Cancer Brief — Daraxonrasib trial doubles survival — access expanding now
Welcome to Matters.com™ beta. A new social platform to share what matters. More information? Click here.
This week brings a major clinical result that changes treatment options for advanced pancreatic cancer and immediate implications for patients who may qualify. I’ll highlight what’s new, who can access it now, and other developments that touch genetics and combination strategies.
Daraxonrasib doubles survival in trial; clinicians can seek access
An experimental KRAS-targeting drug, daraxonrasib, showed a survival benefit roughly double that of standard chemotherapy in a recent trial and is now being offered to some patients outside formal trials. Clinicians can apply for access for advanced-stage patients while regulatory review continues; this changes immediate treatment choices for eligible people and focuses attention on KRAS-directed approaches. Read the primary coverage for details on eligibility and next steps: what doctors are saying and patient access options.
New single-cell tumor atlas
A landmark single-cell map of the tumor microenvironment identifies cell subtypes and interactions that could guide more effective combination immunotherapies for pancreatic cancer; researchers say it refines potential targets for overcoming the tumor’s immune resistance. Read more: study overview.
Pharma buys tech to target 'undruggable' proteins
Johnson & Johnson paid $1 billion for a platform aimed at targeting proteins once considered undruggable, a move that could accelerate drugs addressing mutations central to pancreatic cancer biology. Details here: acquisition report.
BRCA2 and pancreatic cancer risk
Germline BRCA2 mutations increase an individual’s lifetime risk of pancreatic cancer; carriers are also more likely to respond to certain DNA-damage–targeting therapies such as platinum chemotherapy and PARP inhibitors. Genetic testing can therefore affect both screening recommendations and treatment choices.